Hepdart.com CELEBRATING 20 YEARS OF HCV RESEARCH

www.hepdart.com
2009
December 6-10, 2009
The fairmont Orchid
Kohala Coast, Big Island, Hawaii, USA
This program is sponsored by Emory University School of Medicine
The 8th biennial meeting
in the HEP DART series
CELEBRATING 20 YEARS OF HCV RESEARCH
Since 1995, the biannual HEP DART Conference has provided
unique, intimate setting that assemble clinicians, researchers and
basic scientists together to advance our knowledge of the ongoing
drug development processes in the treatment of hepatitis B and
hepatitis C and other viruses affecting the liver, including co-infections with HIV.
The 2009 DART CME-accredited Conference will uniquely blend the areas of
virology, biology, chemistry, pharmacology and clinical research to provide the
scientific community with an increased understanding of the current and future
challenges in therapeutics for hepatitis infection.
Program Information
WILLIAM H. PRUSOFF HEP DART LIFETIME
ACHIEVEMENT AWARD AND LECTURE
Reflections on the 20th Anniversary of the Discovery of HCV
Michael Houghton, Epiphany Biosciences, USA
STATE OF THE ART PRESENTATIONS
The Future Burden of Chronic Liver Disease and Global Opportunities for
Therapeutic Interventions
Brian McMahon, Alaska Native Medical Center and Alaska Native Tribal Health
Consortium, USA
HBV Resistance - Prevention and Monitoring
Anna Lok, University of Michigan Medical Center, USA
Understanding Stat-C by Using Cell Culture Models
Ralf Bartenschlager, University of Heidelberg, Germany
Optimization of Anti-HCV Regimens
Michael Fried, University of North Carolina at Chapel Hill, USA
Pharmacology of Anti-HBV and Anti-HCV Drugs
Adrian Ray, Gilead Sciences, Inc., USA
Prevention of HCC in Hepatitis B Patients Using Antiviral Agents
Yun-Fan Liaw, Chang Gung Memorial Hospital, Taiwan
PANEL PRESENTATIONS
Additionally, HEP DART will include the following panel presentations:
• Perspectives of Global and US Regulatory Authorities: Combination
Chemotherapy: Life after Interferon
• The Business of Antiviral Agents, 2010 and Beyond
2009
December 6-10, 2009
The fairmont Orchid
Kohala Coast, Big Island, Hawaii, USA
IMPORTANT DATES
Conference dates
December 6-10, 2009
Early registration deadline
October 2, 2009
Abstract submission deadline
October 2, 2009
Abstract acceptance notification
October 19, 2009
Final date for online registration
December 2, 2009
Opening session - 15:00
December 6, 2009
Closing session
December 10, 2009
TOWARD CURATIVE THERAPIES FOR HEPATITIS C: A
SATELLITE MINI-SYMPOSIUM
HEP DART attendees have a chance to hear about new developments in
HCV therapeutics including combined modalities from industry leaders
as well as their future plans. The mini-symposium is being held at 09:00
on December 6, 2009 prior to the official start of HEP DART 2009.
2009
December 6-10, 2009
The fairmont Orchid
Kohala Coast, Big Island, Hawaii, USA
HISTORY & MANAGEMENT
Brian McMahon, Alaska Native Medical Center and Alaska Native
Tribal Health Consortium, USA
Mostafa Mohamed, AinShams University, Egypt
Hashem el-Serag,
Kenneth Sherman, University of Cincinnati College of Medicine, USA
DISCOVERIES & ADVANCES IN HCV BASIC RESEARCH
Michael Houghton, Epiphany Biosciences, USA
Alan Perelson, Los Alamos National Laboratory, USA
Timothy Tellinghuisen,
NEW TARGETS I: INSIGHTS INTO DRUG MECHANISMS
Charles Rice,
Jordan Feld, Toronto Western Hospital Liver Centre, University of
Toronto, Canada
Philippe Gallay,
Stanley Lemon, University of Texas Medical Branch at Galveston, USA
Peter Sarnow, Stanford University, USA
HCV MANAGEMENT: LOOKING INTO THE CRYSTAL BALL
Jean-Michel Pawlotsky, Henri Mondor University Hospital, France
David Nelson, University of Florida, USA
Adrian Di Bisceglie, Saint Louis University School of Medicine, USA
Adam Cutler, Canaccord Adams, USA
JP Morgan Securities, Inc.
Abel De La Rosa, Pharmasset, Inc., USA
Vivek Ramaswamy, QVT Financial LP, USA
David Witzke, PioneerPath Capital, USA
Frank Zavrl, Adage Capital, USA
Anna Lok, University of Michigan Medical Center, USA
Stephen Locarnini, VIDRL, Australia
Philippe Halfon, Hospital Ambroise Paré, France
Isabel Najera, Roche Palo Alto, USA
Robert Gish, CPMC, USA
CLINICAL TRIAL DESIGN
Paul Pockros,
Douglas Dieterich, Mount Sinai School of Medicine, USA
REVIEW OF POSTER PRESENTATIONS
Adrian Ray, Gilead Sciences, Inc., USA
Adrian Di Bisceglie, Saint Louis University School of Medicine, USA
HEPATITIS B FOUNDATION SYMPOSIUM: CO-INFECTIONS,
Gregory Dore, University of New South Wales, Australia
Mark Sulkowski, Johns Hopkins University, USA
Richard Robson, Christchurch Clinical Studies Trust, New Zealand
NEW TARGETS II: CELL CULTURE AND ANIMAL MODELS
FOR HCV
Ralf Bartenschlager, University of Heidelberg, Germany
Center for Experimental and Clinical Infection
Research, Germany
Alexander Ploss,
HEPATITIS INFECTIONS
Michael Fried, University of North Carolina at Chapel Hill, USA
Yves Benhamou, Hôpital Pitié-Salpêtrière, France
Patrick Marcellin, Hôpital Beaujon, France
Jules Dienstag,
HEPATITIS INFECTIONS
Adrian Ray, Gilead Sciences, Inc., USA
Robert Schooley, University of California San Diego, USA
IMMUNOLOGICAL APPROACHES & VACCINES FOR
HEPATITIS INFECTIONS
Luke O’Neill, Trinity College Dublin, Ireland
T. Jake Liang, NIDDK National Institutes of Health, USA
Frank Chisari,
Christoph Seeger, Fox Chase Cancer Center, USA
LIVER DAMAGE, DECOMPENSATION FIBROSIS &
HEPATOCELLULAR CARCINOMA
Yun-Fan Liaw, Chang Gung Memorial Hospital, Taiwan
William Mason, Fox Chase Cancer Center, USA
Masao Omata, University of Tokyo, Japan
Nezam Afdhal, Beth Israel Deaconess Medical Center, USA
Hôpital Pitié-Salpêtrière, France
University of Miami, USA
Please visit the conference website at:
www.HEPDART.com
Timothy Block, Hepatitis B Foundation and Drexel University, USA
2009
December 6-10, 2009
The fairmont Orchid
Kohala Coast, Big Island, Hawaii, USA
REGISTRATION (limited to 400 persons)
The Organizing Committee strongly suggests that you register early to
ensure your confirmation, as registration will close when the capacity
of the venue is reached. Priority will be given to persons submitting an
abstract.
On-line registration is available on the Conference website at
www.HepDART.com.
Payment of the Conference registration fee includes the following:
• Entrance into all scientific sessions, including poster area
• Delegate bag, including abstract book and final program
• Welcome reception following the Opening Session on
Sunday, December 6, 2009
• Breakfasts on Monday-Thursday, December 7-10, 2009
• Refreshment breaks on Monday-Thursday, December 7-10, 2009
• Lunch on selected days
• Gala Party
• Poster Session Reception
EARLY REGISTRATION
(registration must be received on or before Friday, October 2, 2009)
Conference registration fee: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . US $730
Academic/Government/Non-profit organization: . . . . . . . . . . . US $630
Accompanying guests: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . US $300
REGULAR REGISTRATION
(register on or before Wednesday, December 2, 2009)
Conference registration fee: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . US $930
Academic/Government/Non-profit organization: . . . . . . . . . . . US $830
Accompanying guests: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . US $400
CANCELLATION POLICY
Please note that cancellation of r • egistrations received or postmarked
on or before October 6, 2009 will incur a $50 administration fee.
• Cancellation of registrations received or postmarked after
October 6, 2009 and on or before October 30, 2009 will incur a fee
equivalent to 50% of the registration payment and 50% of the hotel
deposit.
• No refund of the registration payment and hotel deposit will be
issued for cancellations postmarked after October 30, 2009.
CONTINUING MEDICAL EDUCATION
Accreditation Statement
Emory University School of Medicine is accredited by the
Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
Credit Designation Statement
Emory University School of Medicine designates this educational
activity for a maximum of 25 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the extent of
their participation in the activity.
CONFERENCE OBJECTIVES
The Scientific Committee has designed the Conference program to
ensure that the delegates achieve the following objectives:
• Understand the role of viral targets in the drug development and
discovery process
• Identify the next generation of inhibitors of viral hepatitis
• Assess the impact of resistance and treatment failure in the drug
development and discovery process
• Increase awareness of the clinical impact of antiviral agents
• Understand the consequences of co-infection with HIV on the
management of patients
• Assess the role of vaccines and therapeutic vaccines in future
therapies for viral hepatitis
TARGET AUDIENCE
The Conference is open to anyone interested in therapies for viral
hepatitis. However, the content of this Conference was developed to
interest primarily scientists and clinical researchers in the infectious
diseases.
Abstract Submission
The Scientific Committee requests that authors submit their abstracts
electronically via the Conference website at www.HepDART.com.
For complete instructions regarding abstract submittal, please visit the
Conference website. The abstract submission deadline is
October 2, 2009.
For purposes of review and programming, abstracts are divided into
topical categories. Selection of the most appropriate category is
important as it determines who reviews your abstract. The Organizing
Committee reserves the right to reassign your abstract to a more
appropriate category.
• Advances in HCV and HBV Cell-based Assays & Animal Models
• Clinical Development of HBV/HCV Inhibitors
• Co-infection with HIV and Other Viruses
• Hepatocellular Carcinoma and Fibrosis
• Immunology & Vaccine Development
• Next Generation of HBV and HCV Inhibitors
• New Therapeutic Approaches, Combinations, Pharmacology, and
Emerging Targets
• Optimizing Outcome of Therapeutics for HBV/HCV
• Pathogenesis, Therapeutics, Viral Dynamics and Emerging Viruses
• Resistance to Antiviral Agents, Replication Fitness and Vaccine
Escape Mutants
• Diagnostic Approaches and Non-invasive Markers
HEP DART 2009 is supported by independent educational grants from the following:
Alios BioPharma, Inc.
Apath, LLC
Department of Veterans Affairs
Raymond F. Schinazi & Family Foundation
Samchully Pharm. Co., Ltd
PREMIER SUPPORT
GOLD SUPPORT
SILVER SUPPORT
BRONZE SUPPORT
ADDITIONAL SUPPORT